ການທົບທວນຄືນທີ່ຂຽນໂດຍ Young, MD, Anderson Cancer Center, USA ໄດ້ອະທິບາຍເຖິງການໃຊ້ຢາຕ້ານເຊື້ອ PD-1 inhibitor ໃນ lymphoma B-cell. (ເລືອດ. ສະບັບວັນທີ 8 ພະຈິກ 2017. doi: 10.1182 / blood-2017-07-740993.) PD-1 immune..
ຄລີນິກ Cleveland ຂອງສະຫະລັດ Eric D. His et al. ລາຍງານວ່າການວິນິດໄສຂອງມະເຮັງຕ່ອມລູກຫມາກ peripheral T cell (PTCL) ໃນສະຫະລັດມີຄວາມແຕກຕ່າງກັນຢ່າງຫຼວງຫຼາຍ, ແລະມັກຈະຂາດຂໍ້ມູນ phenotypic ທີ່ສໍາຄັນເພື່ອຈໍາແນກຢ່າງເຕັມສ່ວນ.
ເນື້ອງອກ T-cell ແກ່, ເຊັ່ນ: lymphoma ທີ່ບໍ່ແມ່ນ Hodgkin T-cell, ມີການຮຸກຮານສູງແລະທົນທານຕໍ່ຢາ, ແລະຄົນເຈັບມັກຈະມີການຄາດຄະເນທີ່ບໍ່ດີ. ບໍ່ດົນມານີ້, ຊຸດ "ທໍາມະຊາດ" ຂອງສອງບົດຄວາມຈັດພີມມາການຕີຄວາມໃຫມ່ຂອງເຊື້ອພະຍາດ..
Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system),..
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III or IV classic Hodgkin's lymph..
ການຄົ້ນຄວ້າ New Cleveland Clinic ສະແດງໃຫ້ເຫັນເປັນຄັ້ງທໍາອິດວ່າ ibrutinib (ibrutinib) ທີ່ໄດ້ຮັບການອະນຸມັດຈາກ FDA ສໍາລັບ lymphoma ແລະ leukemia ອາດຈະຊ່ວຍປິ່ນປົວເນື້ອງອກໃນສະຫມອງທີ່ພົບເລື້ອຍທີ່ສຸດແລະຕາຍ, ແລະມື້ຫນຶ່ງອາດຈະຖືກນໍາໃຊ້ໃນຄົນເຈັບທີ່ມີ gliobla.
Bone marrow fibrosis is a rare chronic disease of bone marrow hematopoietic cells. They benefit from JAK2 inhibitor drugs: symptom relief, prolonged survival, and improved quality of life. However, two or three years after starti..
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytruda, pembrolizumab) for the trea..
In the United States, more than 70,000 people are diagnosed with non-Hodgkin's lymphoma each year, which is caused by excessive proliferation of immune cells in the body's lymph nodes. The most common is diffuse large B-cell lymp..
ໃນຊຸມປີມໍ່ໆມານີ້, ຜົນກະທົບຂອງຕົວຍັບຍັ້ງກວດເຂດພູມຕ້ານທານໃນການຮັກສາໂຣກ Lymphoma (H) ຂອງ Hodgkin ແມ່ນ ໜ້າ ປະທັບໃຈ, ແຕ່ວ່າພະຍາດດັ່ງກ່າວຍັງຕ້ອງໄດ້ເອົາຊະນະຢ່າງລະອຽດຕື່ມອີກ. ກຸ່ມບໍລິສັດ Lymphoma Group ຂອງ Mayo Clinic ຈະໄດ້ຮັບການຕອບຮັບໄວ.